Abcam, ab144651, Pitstop® 1-25, clathrin inhibitor

Size: 5mg
MW 405.5 Da, Purity >99%. Novel, selective clathrin inhibitor. Inhibits the clathrin terminal domain (IC50 = 6.9 μM). No inhibition seen with dynamin and other key clathrin mediated endocytosis pathway proteins. Low cell permeability. Related products Pitstop® 2 (ab120687), Pitstop® 1 (ab120686) and Pitstop® 2-100 (ab144650).
Key facts
CAS number:1419321-16-6,
Purity:>99%,
Form:SolidSee storage information,
Molecular weight:405.5 Da,
Molecular formula:C19H12KNO5S,
PubChem:75593424,
Nature:Synthetic,
Solubility:Soluble in DMSO,
Biochemical name:Clathrin-IN-25,
Biological description:Novel, selective clathrin inhibitor. Inhibits the clathrin terminal domain (IC50 = 6.9 μM). No inhibition seen with dynamin and other key clathrin mediated endocytosis pathway proteins. Low cell permeability. Related products Pitstop® 2 (ab120687), Pitstop® 1 (ab120686) and Pitstop® 2-100 (ab144650).,
Canonical smiles:C1=CC=C(C=C1)CN2C(=O)C3=CC=CC4=CC(=CC(=C43)C2=O)S(=O)(=O)[O-].[K+],
InChi:InChI=1S/C19H13NO5S.K/c21-18-15-8-4-7-13-9-14(26(23,24)25)10-16(17(13)15)19(22)20(18)11-12-5-2-1-3-6-12;/h1-10H,11H2,(H,23,24,25);/q;+1/p-1,
InChiKey:XOIYIOVSMFKQQC-UHFFFAOYSA-M,
IUPAC Name:potassium;2-benzyl-1,3-dioxobenzo[de]isoquinoline-5-sulfonate

Product details:
Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. Pitstop® is a trademark of Freie Universitat Berlin, Newcastle Innovation Ltd. and Children's Medical Research Institute.

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Clathrin heavy chain also known as clathrin heavy chain 1 or heavy chain kDa is a fundamental component of the clathrin protein complex with a molecular weight commonly around 180 kDa. This chain-like protein mechanically assembles into a triskelion shape consisting of three heavy chains and three light chains allowing it to form a lattice structure that coats vesicles. Clathrin heavy chain is expressed widely especially in cells with high endocytic and vesicle transport activity like neuronal and epithelial cells. It plays a pivotal role in cellular trafficking by driving the formation of clathrin-coated pits and vesicles.
Biological function summary
Functions of the clathrin heavy chain include mediating the endocytosis of receptors and other membrane proteins contributing to intracellular sorting and vesicle trafficking. It is a part of the clathrin triskelion complex which is essential for maintaining proper cellular homeostasis. The clathrin lattice structure dynamically assembles and disassembles to facilitate the transport of molecules from the plasma membrane to the endosomes influencing endocytic and post-Golgi network trafficking processes. This protein's ability to form complexes enables efficient cargo selection and vesicle scission.
Pathways
Clathrin-mediated endocytosis serves as a critical pathway for internalizing substances and is fundamental in the regulation of signal transduction pathways and receptor recycling. The clathrin heavy chain interacts closely with proteins such as adaptins and dynamin in these pathways to ensure accurate vesicle budding and trafficking. In synaptic vesicle recycling clathrin collaborates with proteins like synaptotagmins to manage neurotransmitter release maintaining synaptic transmission and neuronal function.
Disruptions in clathrin heavy chain function can lead to conditions such as neurodegenerative diseases and cancer. For instance alterations in clathrin-mediated endocytosis can affect receptor trafficking and signaling contributing to Alzheimer’s disease. Similarly aberrant clathrin function can influence cell cycle control and apoptosis pathways involved in cancer progression. In cancer the regulation of the epidermal growth factor receptor (EGFR) by clathrin-dependent endocytosis highlights the complex interplay between clathrin and oncogenic signaling pathways.